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Background: The somatic molecular profiles of basal-like breast cancers and high-grade serous ovarian cancers share many
similarities, leading to the hypothesis that they have similar aetiologies, in which case they should occur together in the same
patient more often than expected.
Methods: We identified 545 women with double independent primary cancers of the breast and ovary reported to the California
Cancer Registry from 1999 to 2013 and examined the coincidence of subtype combinations.
Results: For most subtype combinations the observed frequencies were similar to their expected frequencies, but in 103 observed
cases vs 43.8 expected (O/E¼ 2.35; 95% CI 1.90–2.81) a triple-negative breast tumour (typically basal-like) was matched with a
serous ovarian tumour (typically high-grade).
Conclusions: The results provide compelling evidence that basal-like breast cancer and high-grade serous ovarian cancer share a
much more similar aetiology than breast and ovarian cancers more broadly. Further research is needed to clarify the influence of
germ-line BRCA1 mutations and other risk factors on these results.
In recent years, investigators have paid increasing attention to the
sub-classification of cancer. In a detailed analysis in The Cancer
Genome Atlas (TCGA), the molecular portrait of basal-like breast
cancers was observed to have similar characteristics to that of high-
grade serous ovarian tumours (Cancer Genome Atlas Network,
2012). Both subtypes exhibited a very high frequency of TP53
mutations, evidence of mutations in NF1 and RB1 at lower
frequencies, BRCA1 and BRCA2 inactivation, and similar copy
number gains and losses. Bioinformatic pattern recognition
methods have also suggested that these tumour types are
characterised by mutually exclusive loss of function in the same
pathways (Cancer Genome Atlas Network, 2012; Ciriello et al,
2012). The authors of the TCGA report of breast cancer suggested
that these results ‘indicated a related aetiology’ of these tumour
subtypes (Cancer Genome Atlas Network, 2012). Our purpose was
to test this hypothesis by assessing whether triple-negative breast
cancers (as a surrogate for basal-like tumours) and serous ovarian
cancers (most of which are high-grade) occur together more
frequently in the same patient than expected. Our premise is that if
risk profiles of two subtypes are correlated in the population, then
these subtypes are more likely to co-occur in the same patient
(Begg, 2011).
MATERIALS AND METHODS
Since 1999, the California Cancer Registry has routinely collected
information on breast tumour markers, including oestrogen
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receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2). These markers can be used to
approximately classify patients into four breast cancer subtypes:
luminal A (ERþ or PRþ , and HER2 ); luminal B (ERþ
or PRþ , and HER2þ ); HER2 enhanced (ER , PR and
HER2þ ); and triple negative (ER , PR and HER2 ). The
California Cancer Registry also collected information on histologic
subtypes of epithelial ovarian cancer, including the four most
common subtypes: serous; endometrioid; mucinous; and clear cell.
We obtained the frequencies of the subtypes of all incident cases of
either cancer during the period 1999–2013, as well as the
frequencies and subtypes of all cases with multiple primaries. We
then used these data to compare the observed vs expected co-
occurrences of all subtype combinations among all women
diagnosed with both a primary breast cancer and a primary
ovarian cancer.
For each of the 16 possible combinations of subtypes of the two
diseases, we enumerated the observed number of cases with the
specific subtype combination. This observed total was then divided
by an expected value to determine which subtype combinations
occurred more frequently together than expected. The expected
values were calculated by multiplying the total number of observed
cases with both a breast and an ovarian primary by the relative
frequencies of the specific subtypes observed among all cases of
cancer. These relative frequencies are provided in Supplementary
Table 1. The resulting O/E ratio represents a ratio of two
standardised incidence ratios. The denominator is a measure of
how strongly the aetiologies of breast and ovarian cancer overall
are related, while the numerator reflects the corresponding
strength of the relationship between the two subtypes under
consideration. Thus, if the O/E ratio is elevated it suggests that the
two subtypes share a more similar aetiology than breast and
ovarian cancers overall, and vice versa. The rationale for these
calculations is explained in detail in the Supplementary Methods.
RESULTS
We excluded ovarian adenocarcinomas or carcinomas with
histology designated as ‘other’ and restricted the analysis to breast
cancers for which tumour markers were available (74% of all breast
cancer cases). Our final analytic sample included 545 women with
one breast and one ovarian primary cancer that had known
subtypes, but excluded 72 paired breast–ovary tumours from cases
with three or more primaries and five synchronous cases. The
results were not materially affected by these exclusions (data not
shown). The observed and expected values for all subtype
combinations are provided in Table 1. The results show a large
2.35-fold increase over expectation in the co-occurrence of triple-
negative breast cancers with serous ovarian cancers. None of the
other combinations of subtypes demonstrated any convincing
trends, although in three combinations the co-occurrence was
marginally significantly lower than expected (luminal B breast and
serous ovarian; luminal A and mucinous; and luminal A and
endometrioid). However, as the total observed and expected
frequencies are constrained to be equivalent, the other combina-
tions must compensate with lower observed rates to offset the large
excess co-occurrence of serous ovarian and triple-negative breast
cancers.
When we stratified by order of diagnosis (breast cancer first vs
ovarian cancer first), we observed significantly elevated occurrence
of the triple-negative breast/serous ovarian cancer double primary
combination in both strata. When the breast cancer occurred first,
there were 73 cases observed vs 25.9 expected (O/E¼ 2.8, 95%
confidence interval 2.2–3.5), and when the ovarian cancer was
diagnosed first there were 30 observed vs 17.9 expected (O/E¼ 1.7,
95% confidence interval 1.1–2.3).
DISCUSSION
These results provide compelling support for the hypothesis that
the risk profiles for basal-like breast cancer and high-grade serous
ovarian cancer are strongly correlated. That is, individuals with a
high risk for basal-like breast cancer will typically also experience a
high risk for high-grade serous ovarian cancer, and vice versa. This
knowledge should facilitate a purposeful search for the risk factors
common to these subtypes. Relatively little is known about risk
factors specifically for high-grade serous and basal-like breast
cancers. Although reproductive and hormonal risk factors do not
clearly overlap between serous and triple-negative breast cancer,
what is highly consistent is that established hormonal risk factors
for breast and ovarian cancers overall are much more weakly
associated with these subtypes compared to other breast or ovarian
subtypes (Anderson et al, 2014; Wentzensen et al, 2016).
Table 1. Observed vs expected counts for combinations of subtypes in double primary cases of breast and ovarian cancers
Double primary cases
Breast subtype Ovarian subtype Observed Expecteda Ratiob 95% confidenceb
Luminal A Serous 236 245.1 0.96 0.84–1.09
Endometrioid 50 64.3 0.78 0.56–0.99
Clear cell 27 31.4 0.86 0.54–1.18
Mucinous 26 37.1 0.70 0.43–0.97
Luminal B Serous 32 43.1 0.74 0.49–1.00
Endometrioid 9 11.3 – –
Clear cell 7 5.5 – –
Mucinous 7 6.5 – –
HER2 enhanced Serous 25 21.2 1.18 0.72–1.64
Endometrioid 2 5.6 – –
Clear cell 2 2.7 – –
Mucinous 1 3.2 – –
Triple negative Serous 103 43.8 2.35 1.90–2.81
Endometrioid 13 11.5 1.13 0.52–1.74
Clear cell 4 5.6 – –
Mucinous 1 6.6 – –
aThe expected frequencies were computed by multiplying the total number of double primaries observed (545 cases) by the two relative frequencies of the designated subtypes derived from
all incident single primary cancers. These frequencies are provided in Supplementary Table 1.
bWe omitted the statistical inferences for subtype combinations that occurred fewer than 10 times. The bold entries represent the key findings of the article.
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An obvious candidate that may explain a portion of the risk
association is the presence of a BRCA1 germ-line mutation.
Previous studies have shown that germ-line mutations in BRCA1
are more frequent in serous ovarian cases than other ovarian
subtypes, and considerably more frequent in triple-negative breast
cases than other breast cancer subtypes, suggesting that BRCA1
germ-line mutations represent an important risk factor that
explains a portion of the elevated concordance between triple-
negative breast and serous ovarian cancers in our study (Mavaddat
et al, 2012). Further, although the prevalence of BRCA1 mutations
in the USA population is low, the high relative risks of breast
and ovarian cancer among mutation carriers lead to much higher
prevalences of germ-line BRCA1 mutations in cases, and
especially in those with double primaries. While among breast
cancer patients in northern California the prevalence of BRCA1
mutations is only about 2% (John et al, 2007), the prevalence
in ovarian cancer patients is higher (B13% for BRCA1 and
BRCA2 combined) (Arts-de Jong et al, 2016) and the reported
prevalence in cases with double breast–ovary primaries is higher
still, in the region of 35% (Evans et al, 2010; Cvelbar et al, 2011;
Pilarski et al, 2012). Clearly, a study involving genotyping would
be necessary to resolve the extent to which these mutations may
explain the increased similarity of the risk profiles of basal-like
breast and high-grade serous ovarian cancers. Conversely, there
are also important distinctions between these subtypes in that by
definition triple-negative tumours are ER negative, whereas
serous ovarian tumours are predominantly ER positive, suggest-
ing that while there must be important commonalities in their
risk profiles there must also be important differences (Shafrir
et al, 2016).
It is interesting that we did not observe evidence of a shared
aetiology for the other subtype combinations, even though, for
example, luminal breast cancers and endometrioid ovarian cancers
are characterised by hormone receptor expression (Anderson et al,
2014) and have similar reproductive risk factors (Hecht et al,
2009).
One limitation of our study is that treatment for the first
primary cancer could differentially impact incidence of subtypes of
the second primary tumour. For example, bilateral oophorectomy
for ovarian cancer treatment may lower the incidence of
hormonally sensitive luminal A breast tumours more than triple-
negative tumours (Press et al, 2011; Boggs et al, 2014). Subtype
misclassification is also an issue, although ovarian cancer histology
is reasonably well classified and subtyping for breast cancer was
relatively standardised during the period of our study (Ko¨bel et al,
2013). Further, we used triple-negative breast cancers as a
surrogate for basal-like, recognising that only about 80% of triple
negatives will be truly basal-like (Rakha and Ellis, 2009; Curtis et al,
2012). While we were unable to characterise serous ovarian cancer
by grade, few serous tumours are low-grade (Matsuno et al, 2013).
Despite these potential sources of bias, we believe that the results
are sufficiently strong that they provide substantial evidence of the
common aetiology of basal-like breast cancer and high-grade
serous ovarian cancer. It is critical to identify both shared and non-
shared risk factors for high-grade serous and basal-like breast
cancer as these are the most aggressive types of these cancers.
Further research should examine risk factor profiles of tumours
across anatomic sites that share molecular features.
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